The FDA determined that Novo Nordisk’s obesity and diabetes drugs are no longer in short supply. Elsewhere, Concentra made a ...

A lawsuit filed in the Singapore International Commercial Court is seeking $830 million in damages from KBP, with Novo ...

Deutsche Bank (ETR:DBKGn) initiated coverage on shares of Biohaven Pharmaceutical (TADAWUL:2070) Holding (NYSE:BHVN) with a Buy rating and a price target of $65.00. The firm's analysts cited the ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey Sonnenfeld and co-author Steven Tian.

Pfizer has agreed to pay $59,746,277.54, plus interest, to resolve allegations that Biohaven knowingly submitted or caused false claims to be submitted to Medicaid and other federal health care ...

Other recent buys include Biohaven for US$11.6bil and Arena Pharmaceuticals for US$6.7bil. In May, Pfizer embarked on a cost-cutting plan meant to save US$1.5bil by the end of 2027. Still ...

Second, the returns on invested capital from Pfizer’s $11 billion Biohaven transaction have also already exceeded the most optimistic internal estimates, with Nurtec sales growing exponentially en ...

Tong’s office said Pfizer had agreed to pay the sum on behalf of New Haven-based Biohaven to resolve allegations that Biohaven had knowingly submitted or caused to be submitted false claims to ...

Florida's Medicaid Fraud Control Unit secured the win through a multistate action. Pharmaceutical giant Pfizer will be paying more than $2.3 million on behalf of its wholly owned subsidiary ...

30, 2022. Pfizer announced its plans to acquire Biohaven Pharmaceuticals in May 2022. The pharmaceutical juggernaut’s largest manufacturing facility is in Portage, Michigan, which employs ...

The $59,746,277 settlement resolves a federal court case that Connecticut and 37 other states and Puerto Rico had joined against Biohaven Pharmaceutical Holding Company Ltd., a Pfizer-owned local ...

After a period of unsteady sales for its key COVID-19 products, Pfizer now sees COVID-related revenue volatility as “largely in the past.” In an investor presentation (PDF) Tuesday ...